AI Article Synopsis
- Molecular targeted therapies using monoclonal antibodies against PD-L1 and PD-1 have improved cancer treatment outcomes, with PD-L1 expression levels serving as a predictor for patient response.
- A study involving 137 non-small cell lung cancer patients found a strong correlation in PD-L1 staining results between two antibody types (22C3 and 28-8), with no significant differences in staining based on the age of tissue samples.
- Ultimately, the time between tissue collection and analysis did not impact PD-L1 immunoreactivity, suggesting consistent reliability in testing regardless of storage duration.
Article Abstract
Background: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD-L1 and PD-1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD-L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD-L1 in non-small cell lung cancer (NSCLC).
Methods: This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28-8 antibodies.
Results: There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28-8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28-8 antibodies was observed. The immunoreactivity rate achieved with 22C3 or 28-8 antibodies significantly correlated with tumor histological type and size, but not with specimen storage time, age, gender, smoking history, clinical stage, or lymph node metastasis.
Conclusion: In brief, the results of this study show that the time interval between tissue sampling/paraffinization and immunohistochemical analysis has no influence on the immunoreactivity rate of PD-L1 in NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209791 | PMC |
| http://dx.doi.org/10.1111/1759-7714.12861 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of PD-L1 assays in head and neck carcinoma.
Pathology
December 2024
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address:
Article Synopsis
- PD-L1 expression serves as a crucial biomarker in predicting how patients with head and neck squamous cell carcinoma might respond to immune checkpoint inhibitors, making it important to evaluate different testing methods.
- A study conducted at Asan Medical Center evaluated PD-L1 expression in 156 cases using various standardized assays and a laboratory-developed test, revealing good to excellent agreement among the methods.
- The results highlighted that PD-L1 expression significantly varies with tumor location and suggests that the different assays could potentially be used interchangeably for assessing PD-L1 in head and neck cancers.
Programmed death-ligand 1 expression in carcinoma of unknown primary.
BMC Cancer
June 2024
Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
Article Synopsis
- - The study focused on the expression of PD-L1 in carcinoma of unknown primary (CUP) by analyzing tissue samples from 72 cases, using various immunohistochemical methods.
- - The PD-L1 positivity rates in CUP varied significantly depending on the antibodies used, with rates ranging from 5.6% to 48.6%, but these rates did not change with different histologic or clinical subtypes.
- - Analysis showed that while PD-L1 expression was inconsistent across various scoring systems, there was a fair level of agreement between different antibodies used in the study.
Purpose: The clinical application of PD-L1 immunohistochemistry (IHC) testing is complicated by the availability of multiple IHC assays, scoring algorithms, and cutoffs. This study assessed the analytical comparability of three commercially available PD-L1 assays and two scoring algorithms used to assess PD-L1 status in gastric cancer (GC) samples.
Methods: Serial sections of 100 resected GC samples, with PD-L1 expression levels across the dynamic range, were stained with three in vitro diagnostic-grade PD-L1 assays (28-8, 22C3, and SP263).
Performance Analysis of Leica Biosystems Monoclonal Antibody Programmed Cell Death Ligand 1 Clone 73-10 on Breast, Colorectal, and Hepatocellular Carcinomas.
Appl Immunohistochem Mol Morphol
July 2024
Medical and Scientific Affairs, Leica Biosystems Richmond Inc., Deer Park, IL.
Programmed cell death receptor 1/Programmed cell death ligand 1 (PD-L1) checkpoint pathway is responsible for the control of immune cell responses. Immunotherapy using checkpoint inhibitors, such as anti-PD-L1 therapy, aids disease management and potentiates clinical outcomes. This study aimed to analyze the performance of the Leica Biosystems (LBS) USA FDA class I in vitro diagnostic monoclonal antibody (clone 73-10) to detect PD-L1 expression in breast, colorectal, and hepatocellular carcinomas compared with the class III FDA-approved PD-L1 detecting antibodies [SP263 (Ventana), 22C3 (Dako), and 28-8 (Dako)] using 208 unique tissue microarray-based cases for each tumor type.
View Article and Find Full Text PDFDiscordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.
Gastric Cancer
July 2024
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Background: We evaluated the concordance/discordance of PD-L1 staining results between the 28-8 and 22C3 assays and its impact on the efficacy outcomes of advanced gastric cancer patients treated with nivolumab plus chemotherapy.
Methods: This retrospective study involved 143 gastric cancer patients treated with first-line nivolumab plus chemotherapy whose PD-L1 results with both 28-8 and 22C3 assays were available. The concordance/discordance between these assays and the inter-observer variability were evaluated for PD-L1 combined positive score (CPS) positivity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!